摘要
为评价Rev.1-ΔKan-Vir B12突变株在BALB/c鼠中的免疫保护力,以Rev.1为参照,用Rev.1-ΔKanVir B12接种BALB/c小鼠,免疫45 d后用布鲁氏菌16M强毒株攻毒,15 d后取BALB/c鼠脾脏进行克脾指数测定和病理组织学检测。结果显示:BALB/c鼠免疫攻毒15 d后,Rev.1-ΔKan-Vir B12免疫组和Rev.1免疫组的克脾指数与对照组之间有显著性差异(P<0.05),而Rev.1免疫组与Rev.1-ΔKan-Vir B12免疫组之间的克脾指数差异不显著(P>0.05)。结果表明,羊布鲁氏菌Rev.1-ΔKan-Vir B12突变株与其亲本Rev.1株的免疫保护性无明显差异,具备作为布鲁氏菌病标记疫苗的潜力。
In order to evaluate protective efficacy of Rev.1-ΔKan-VirB12mutant in BALB/c mice,BALB/c mice were vaccinated with both Rev.1and Rev.1-ΔKan-VirB12,and then were challenged with16M after vaccinated45d.Fifteen days post challenge,the spleens of BALB/c mice were taken for the Brucella load of gram of spleen determination and histopathological examination.Results showed that there was significant difference between Rev.1-ΔKan-VirB12group and Rev.1group and control group(P<0.05).The difference of Brucella load of gram of spleen between Rev.1immune group andKan-VirB12immune group was not significant(P>0.05).The results showed that the protective efficacy of both was nearly same,holding the potential as a vaccine for Brucellosis.
作者
叶锋
马晓菁
刘丽娅
谷文喜
吐尔洪.努尔
易新萍
马俊杰
钟旗
Ye Feng;Ma Xiaojing;Liu Liya;Gu Wenxi;Tuerhong·Nuer;Yi Xinping;Ma Junjie;Zhong Qi(Institute of Veterinary Research,Xinjiang Academy of Animal science,Urumuqi,Xinjiang 830000)
出处
《中国动物检疫》
CAS
2017年第7期100-104,共5页
China Animal Health Inspection
基金
新疆高技术研究发展计划项目(201311102)
新疆公益性科研院所基金(KYGY2016020)
